Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
Latest Information Update: 30 Aug 2019
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 28 Sep 2018 Status changed from recruiting to discontinued.
- 28 Dec 2016 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
- 28 Dec 2016 Status changed from not yet recruiting to recruiting.